This year, on the 19th of July, JSC Grindeks has submitted a statement of claim to Riga District Court against the JSC „Olainfarm” concerning the nullification of the registration of the trademark MIDOLAT МИДОЛАТ (registration number M 60 991) and the prohibition to use the textual designations MIDOLAT and МИДОЛАТ; besides, an application concerning the assignation of temporary means of protection has also been submitted. JSC Grindeks considers, that “Olainfarm” has purposefully created the mentioned trademark, using the mentioned textual designations in commercial activities, so that the customers would have associations with the widely recognized trade marks MILDRONĀTS, МИЛДРОНАТ and MILDRONATE of the JSC Grindeks. This is done, in order to acquire unfair advantage for the distribution of their identical medications in Latvia through solid reputation of the trademarks of the JSC Grindeks.

Having evaluated the application on the assignation of temporary means of protection  against the JSC „Olainfarm”, which has been submitted by the JSC Grindeks, on 26 July, 2010, Riga District Court has decided to satisfy the application of the JSC Grindeks concerning the assignation of temporary means of protection – to seize and recall from trade all available medications of the JSC „Olainfarm”, which are labeled with textual designations MIDOLAT and МИДОЛАТ, as well as to forbid the usage of textual trademark MIDOLAT МИДОЛАТ to the JSC „Olainfarm”.

The JSC Grindeks considers, that the illegal and unfair activities of the JSC “Olainfarm” might cause major losses and damages to the reputation and discernibility of the widely recognized trade marks MILDRONĀTS, МИЛДРОНАТ and MILDRONATE of Grindeks in Latvia, as well as in the European Union.

The Chairman of the Board of JSC Grindeks Jānis Romanovskis points out: “Mildronate® is the most demanded original product of Grindeks in the group of heart and cardiovascular medications. It has gained wide recognition among the doctors and patients of Latvia, Lithuania, as well as Russia and other CIS countries. Grindeks has made significant investments in the research and development of Mildronate® throughout many years. It constantly works to provide the invariably high quality and effectiveness of the product. And we will do everything in order to defend our intellectual property rights, as we consider, that „Olainfarm” has acted in an illegal and unfair manner by creating a product with a similar name, thus using the high reputation and name of Mildronate®, which is a well-known and appreciated product on the market, as well as by decepting customers”.

Mildronate® is the most demanded original product of JSC Grindeks, the leading medication in the group of heart and cardiovascular medications. The market has Mildronate® for over 20 years, and during the last 5 years alone more than 12 millon patients have used this medication. Due to its unique mechanism of action Mildronate®, depending on the prescribed dose, is widely used for the treatment of different heart and cardiovascular diseases, as well as for the improvement of work capacity of healthy people at physical and mental overloads and during rehabilitation period. The doctors and patients evaluate positively the impact of Mildronate®. For many years, Mildronate® has also been acknowledged as the most export-capable product of Latvia.

In 2010, Grindeks has successfully finished the clinical studies on the influence of Mildronate® on the treatment of angina. The studies confirm the effectiveness of Mildronate® in the treatment of angina, when combined with standard therapy and high reliability of a medication.

On Grindeks

Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.

Group consists of four subsidiary companies in Latvia, Estonia and Russia, as well representatives and representative offices in fourteen countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are: the Baltic States, Russia and other CIS countries, Japan, USA. JSC Grindeks shares are listed in the Official List of “Nasdaq OMX Riga”.

Further information:

Ilze Kreicmane
Deputy Manager of the Communications Department, JSC Grindeks
Phone: +371 67083336; +371 26466681
E-mail: ilze.kreicmane@grindeks.lv
www.grindeks.lv